Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Trang

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Current Opinion in Pharmacology|November 13, 2017
Use of Monte Carlo simulation and considerations for PK-PD targets to support antibacterial dose selectionMichael Trang, Michael N Dudley, Sujata M Bhavnani
Antimicrobial Agents and Chemotherapy|April 14, 2025
Population pharmacokinetic analysis of tobramycin in serum and ELF using data from patients with pneumoniaScott A Van Wart, Michael Trang, M Courtney Safir, et al.
Antimicrobial Agents and Chemotherapy|November 21, 2024
Population pharmacokinetic analyses for sulbactam-durlobactam using Phase 1, 2, and 3 dataAnthony P Cammarata, M Courtney Safir, Michael Trang, et al.
Antimicrobial Agents and Chemotherapy|March 23, 2016
Pharmacokinetics-Pharmacodynamics of a Novel β-Lactamase Inhibitor, CB-618, in Combination with Meropenem in an In Vitro Infection ModelBrian D VanScoy, Michael Trang, Jennifer McCauley, et al.
Antimicrobial Agents and Chemotherapy|September 27, 2017
Pharmacokinetics-Pharmacodynamics of CB-618 in Combination with Cefepime, Ceftazidime, Ceftolozane, or Meropenem: the Pharmacological Basis for a Stand-Alone β-Lactamase InhibitorPaul G Ambrose, Brian D VanScoy, Michael Trang, et al.
Antimicrobial Agents and Chemotherapy|January 24, 2019
Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical StudiesMichael Trang, Julie D Seroogy, Scott A Van Wart, et al.
Antimicrobial Agents and Chemotherapy|July 31, 2024
Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infectionsSujata M Bhavnani, Jeffrey P Hammel, Elizabeth A Lakota, et al.
Antimicrobial Agents and Chemotherapy|April 29, 2020
Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 DataElizabeth A Lakota, Scott A Van Wart, Michael Trang, et al.
Antimicrobial Agents and Chemotherapy|March 22, 2023
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzaeSujata M Bhavnani, Jeffrey P Hammel, Elizabeth A Lakota, et al.
Molecular Cancer Therapeutics|June 23, 2019
MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid TumorsGiuseppe Merlino, Alessio Fiascarelli, Mario Bigioni, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Current Opinion in Pharmacology|November 13, 2017
Use of Monte Carlo simulation and considerations for PK-PD targets to support antibacterial dose selectionMichael Trang, Michael N Dudley, Sujata M Bhavnani
Antimicrobial Agents and Chemotherapy|April 14, 2025
Population pharmacokinetic analysis of tobramycin in serum and ELF using data from patients with pneumoniaScott A Van Wart, Michael Trang, M Courtney Safir, et al.
Antimicrobial Agents and Chemotherapy|November 21, 2024
Population pharmacokinetic analyses for sulbactam-durlobactam using Phase 1, 2, and 3 dataAnthony P Cammarata, M Courtney Safir, Michael Trang, et al.
Antimicrobial Agents and Chemotherapy|March 23, 2016
Pharmacokinetics-Pharmacodynamics of a Novel β-Lactamase Inhibitor, CB-618, in Combination with Meropenem in an In Vitro Infection ModelBrian D VanScoy, Michael Trang, Jennifer McCauley, et al.
Antimicrobial Agents and Chemotherapy|September 27, 2017
Pharmacokinetics-Pharmacodynamics of CB-618 in Combination with Cefepime, Ceftazidime, Ceftolozane, or Meropenem: the Pharmacological Basis for a Stand-Alone β-Lactamase InhibitorPaul G Ambrose, Brian D VanScoy, Michael Trang, et al.
Antimicrobial Agents and Chemotherapy|January 24, 2019
Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical StudiesMichael Trang, Julie D Seroogy, Scott A Van Wart, et al.
Antimicrobial Agents and Chemotherapy|July 31, 2024
Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infectionsSujata M Bhavnani, Jeffrey P Hammel, Elizabeth A Lakota, et al.
Antimicrobial Agents and Chemotherapy|April 29, 2020
Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 DataElizabeth A Lakota, Scott A Van Wart, Michael Trang, et al.
Antimicrobial Agents and Chemotherapy|March 22, 2023
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzaeSujata M Bhavnani, Jeffrey P Hammel, Elizabeth A Lakota, et al.
Molecular Cancer Therapeutics|June 23, 2019
MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid TumorsGiuseppe Merlino, Alessio Fiascarelli, Mario Bigioni, et al.
Pageof 1